中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.033 seconds)

    Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents
    2.
    发明授权
    Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents 有权
    取代的吡唑并[1,5-A]嘧啶作为钙受体调节剂

    公开(公告)号：US09447100B2

    公开(公告)日：2016-09-20

    申请号：US14089747

    申请日：2013-11-25

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Tsuneo Yasuma ,  Akira Mori ,  Masahiro Kawase ,  Hiroyuki Kimura ,  Masato Yoshida ,  Albert Charles Gyorkos ,  Scott Alan Pratt ,  Christopher Peter Corrette

    IPC: C07D487/04 ,  A61K31/519 ,  A61P19/08 ,  A61P19/10

    CPC classification number: C07D487/04

    Abstract: There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; X1 is CR1, CR1R2, N or NR13; X2 is N or NR3; Y is C, CR4 or N, Z is CR5, CR5R6, N or NR7; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and is a single bond or a double bond; R1, R2, R3, R4, R5, R6, R7 and R13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CR5 or N; R8, R9, R10, R11 and R12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X1, R3, R1, Y and X3 in formula (II) and (III) as before.

    Abstract translation: 也如前所述，在式（II）和（III）中指定X1，R3，R1，Y和X3。

    SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS
    5.
    发明申请
    SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS 审中-公开
    作为钙受体调节剂的取代的吡唑并[1,5-A]嘧啶

    公开(公告)号：US20140155416A1

    公开(公告)日：2014-06-05

    申请号：US14089747

    申请日：2013-11-25

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Tsuneo Yasuma ,  Akira Mori ,  Masahiro Kawase ,  Hiroyuki Kimura ,  Masato Yoshida ,  Albert Charles Gyorkos ,  Scott Alan Pratt ,  Christopher Peter Corrette

    IPC: C07D487/04

    CPC classification number: C07D487/04

    Abstract: There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; X1 is CR1, CR1R2, N or NR13; X2 is N or NR3; Y is C, CR4 or N, Z is CR5, CR5R6, N or NR7; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and is a single bond or a double bond; R1, R2, R3, R4, R5, R6, R7 and R13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CR5 or N; R8, R9, R10, R11 and R12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X1, R3, R1, Y and X3 in formula (II) and (III) as before.

    Abstract translation: 提供了包含式（I）化合物的钙受体调节剂：其中环A是任选取代的5-至7-元环; 环B是任选取代的5-至7-元杂环; X1是CR1，CR1R2，N或NR13; X2是N或NR3; Y为C，CR4或N，Z为CR5，CR5R6，N或NR7; Ar是任选取代的环状基团; R是H，任选取代的烃基等; 并且是单键或双键; R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 13独立地为H，任选取代的烃基; 或其盐或其前药。 式（II）和（III）的化合物：其中环A是任选取代的5-至7-元环; Q为C，CR5或N; R8，R9，R10，R11和R12独立地为氢，任选取代的烃基等，或其盐。 也如前所述，在式（II）和（III）中指定X1，R3，R1，Y和X3。

    Medicament for treating heart failure
    6.
    发明授权
    Medicament for treating heart failure 有权

    公开(公告)号：US10786506B2

    公开(公告)日：2020-09-29

    申请号：US16065362

    申请日：2016-12-21

    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

    Inventor： Takahisa Matsuda ,  Takashi Motoyaji ,  Shuji Kitamura ,  Masato Yoshida

    IPC: A61K31/517 ,  A61K31/519 ,  A61P9/04

    Abstract: The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

    MEDICINE
    7.
    发明申请
    MEDICINE 审中-公开

    公开(公告)号：US20200054637A1

    公开(公告)日：2020-02-20

    申请号：US16065362

    申请日：2016-12-21

    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

    Inventor： Takahisa Matsuda ,  Takashi Motoyaji ,  Shuji Kitamura ,  Masato Yoshida

    IPC: A61K31/519 ,  A61P9/04

    Abstract: The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

    Medicament for treating heart failure
    8.
    发明授权
    Medicament for treating heart failure 有权

    公开(公告)号：US10849902B2

    公开(公告)日：2020-12-01

    申请号：US16065362

    申请日：2016-12-21

    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

    Inventor： Takahisa Matsuda ,  Takashi Motoyaji ,  Shuji Kitamura ,  Masato Yoshida

    IPC: A61K31/517 ,  A61K31/519 ,  A61P9/04

    Abstract: The present invention provides a medicament for preventing or treating heart failure. More specifically, the present invention provides a medicament for preventing or treating heart failure, comprising a compound selected from the group consisting of (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)—N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and salts thereof.

Patent Agency Ranking